Jooss Karin
Known title: DirectorCIK: 0001754280
Associated companies
Transaction History
| FATE | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 1,483 | $34K | 6/3/2022 | View on chart |
| FATE | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 1,483 | $34K | 6/3/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial
Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.